Welcome to the Industrial Automation website!

NameDescriptionContent
HONG  KANG
E-mail  
Password  
  
Forgot password?
  Register
当前位置:

The ethics of life sciences and medical research involving people should be examined in this way

来源: | 作者:佚名 | 发布时间 :2023-12-19 | 383 次浏览: | Share:



First, why the Measures?

Adhering to the philosophy of "people first and life first", in order to protect human life and health, safeguard human dignity, respect and protect the legitimate rights and interests of research participants, promote the healthy development of life science and medical research, and regulate the ethical review of life science and medical research involving human beings, The Measures have been formulated in accordance with the Civil Code of the People's Republic of China, the Law of the People's Republic of China on the Promotion of Basic Medical Care and Health, the Law of the People's Republic of China on Science and Technology Progress, the Law of the People's Republic of China on Biosafety, and the Regulations of the People's Republic of China on the Management of Human Genetic Resources.

What specifically does life science and medical research involving human beings include?

The term "life science and medical research involving humans" as mentioned in the Measures refers to the following research activities carried out with human subjects or using biological samples and information data of people (collectively referred to as research participants) :

1, the use of physics, chemistry, biology, traditional Chinese medicine and other methods of human reproduction, growth, development, aging and other research activities;

(2) Research activities on human physiology, psychological behavior, pathological phenomena, etiology and pathogenesis of diseases, as well as the prevention, diagnosis, treatment and rehabilitation of diseases by means of physics, chemistry, biology, traditional Chinese medicine and psychology;

3, the use of new technology or new products on human experimental research activities;

(4) The activities of collecting, recording, using, reporting or storing biological samples, information data (including health records, behaviors, etc.) and other scientific research materials related to human life science and medical problems using epidemiological, sociological, psychological and other methods.

Which organizations should set up ethics review committees, and what are the main considerations?

The Measures stipulate that medical institutions at or above the second level that carry out human life science and medical research, health institutions at or above the municipal level with districts (including disease prevention and control institutions, maternal and child health care, blood collection and supply institutions, etc.), institutions of higher learning, and scientific research institutes should set up ethical review committees.

The main consideration is that the establishment of the ethics review committee is not only a recognition of the research management capacity of the institution, but also a policy obligation that the institution should fulfill. In order to effectively protect the rights and interests of research participants, and fully reflect the professional requirements of ethical review of life science and medical research involving people, the above provisions are made.

Whether and how ethical reviews are required for other institutions to conduct life science and medical research involving humans?

The conduct of life science and medical research involving human beings shall be subject to ethical review as required. In order to achieve comprehensive coverage of the above research ethics review, the Measures provide that if an institution conducts life science and medical research involving human beings without an ethics review committee or if the ethics review committee is unable to meet the needs of the review, the institution may entrust a competent institutional ethics review committee or a regional ethics review committee to conduct an ethical review. It also requires that the commissioned ethics review committee should conduct follow-up reviews of the reviewed studies.

In view of the fact that medical and health institutions mainly carry out clinical research and have higher requirements for risk control, the Measures also require that medical and health institutions should entrust ethical review committees or regional ethical review committees of medical and health institutions not lower than their level to carry out ethical review requirements.

5. How can enterprises conduct ethical review of life science and medical research involving human beings?

The Measures stipulate that where enterprises and institutions cooperate in conducting research, the institutions shall fully understand the overall situation of the research, pass ethical reviews, and carry out follow-up reviews. Companies that conduct research independently can entrust institutional ethics review committees or regional ethics review committees, and achieve extended supervision through follow-up reviews.

6. Are there any special provisions for specific groups in the Measures?

Specific groups of people are the focus of ethical review. In order to strengthen the protection of the rights and interests of specific research participants, the Measures clearly put forward the requirement of "special protection" in the basic requirements of ethical review, and stipulate that special protection should be given to research participants involving specific groups such as children, pregnant women, the elderly, people with intellectual disabilities, and people with mental disabilities. Special attention should be paid to those involving fertilized eggs, embryos, fetuses, or those that may be affected by assisted reproductive technology.

At the same time, the Measures stipulate that the right to know and the autonomy to participate in the research of research participants or their guardians shall be respected and protected, and the use of deception, inducement, coercion and other means shall not be allowed to make research participants or their guardians agree to participate in the research, and the unconditional withdrawal of research participants or their guardians shall be allowed at any stage. In the special chapter on Informed consent, it is further stipulated that if the study participants are persons without or with limited capacity for civil conduct, they shall obtain the written informed consent of their guardians. In addition to obtaining the guardian's consent, the researcher should also inform and obtain the consent of the study participants within the scope of their understanding.

7. How do the Measures and the Measures for the Ethical Review of Biomedical Research Involving Humans apply?

In order to strengthen the legal construction of ethical review of biomedical research involving humans in medical and health institutions and clarify legal responsibilities, the former National Health and Family Planning Commission revised the normative document "Measures for Ethical Review of Biomedical Research Involving Humans (Trial Implementation)" issued by the former Ministry of Health in 2007. In the form of departmental regulations, the "Measures for the Ethical Review of Biomedical Research Involving Humans" (former Order No. 11 of the Health and Family Planning Commission) was issued in 2016. Order No. 11 applies to medical and health institutions at all levels and of all types that carry out biomedical research involving humans, and details administrative penalties for violations.

With the continuous increase of investment in scientific and technological innovation and the development of biotechnology, universities and research institutes are increasingly involved in human life science and medical research. The CPC Central Committee and The State Council attach great importance to safeguarding the rights and interests of research participants, and actively promote the construction of a unified ethical review system. To this end, the NHC, together with the Ministry of Education, the Ministry of Science and Technology, the Bureau of Traditional Chinese Medicine and other relevant departments, formulated the "Measures" to provide a unified ethical review system for medical and health institutions, universities, research institutes and other relevant research to follow, and clearly defined the division of supervision and inspection departments.

The main institutional framework, ethical review methods, informed consent, etc. of the Measures and Decree No. 11 are generally consistent, and some provisions are refined and improved in combination with the requirements of new laws and regulations issued by the State and the actual conditions of universities and research institutes. Within a certain period of time, the specific ethical review practices of institutions may be guided by the Measures; For violations of ethical review in medical and health institutions, health administrative departments at all levels may deal with them on the basis of Order No. 11. The Committee will conduct an in-depth summary of the parallel situation of the Measures and Order 11, and start the revision of Order 11 in a timely manner to further improve supervision. Any other institution violating the provisions shall be dealt with by its superior competent department in accordance with its administrative subordination.

8. Compared with the "Measures for the Ethical Review of Biomedical Research Involving Humans", what are the adjustments to the "Measures for the Ethical Review of Life Sciences and Medical Research Involving Humans"?

The Measures for Ethical Review of Life Science and Medical Research Involving Human Beings adhere to the basic principles and institutional framework of the Measures for Ethical Review of Biomedical Research involving Human beings, including: first, adhere to the main responsibility of institutions, requiring institutions to establish ethical review committees to conduct ethical review of life science and medical research involving human beings; Second, adhere to the two pillars of informed consent and ethical review; The third is to follow internationally recognized ethical norms and adhere to basic ethical requirements. At the same time, combined with the actual situation, it has been optimized and perfected, and put forward a unified follow for different research subjects to carry out life science and medical research involving people.

(1) Expand the scope of application of ethical review, and clarify the regulatory responsibilities of departments in accordance with administrative affiliations. Expand "biomedical research involving people" to "life science and medical research involving people", and bring life science research involving people into the scope of management. Expand the management objects to include medical and health institutions, universities, research institutes, etc., and clarify the regulatory responsibilities of ethical review in accordance with administrative affiliations.

(2) Establish a delegated review mechanism, allowing competent ethical review committees to conduct ethical reviews. First, establish a commissioned review mechanism to achieve comprehensive coverage of ethical review. An institution that does not have an ethics review committee may, in writing, entrust a regional ethics review committee or a competent institutional ethics review committee to conduct an ethics review; The second is to put forward the management requirements of regional ethics review committee, which is an important exploration to further improve the efficiency of ethics review. Third, to carry out research, enterprises can realize ethical review supervision by entrusting ethical review, and clarify supervision and management responsibilities.

(3) Optimize ethical review standards and refine informed consent procedures. The first is to refine the provisions on the informed consent process of the research participants with no capacity or limited capacity. The second is to expand the "subject" to "research participant" according to the progress of biomedical research and bioethics, strengthen the respect for people and expand the scope of protection. The third is to balance regulation and innovation, and set up an institutional arrangement of "exemption from ethical review". Fourth, the time limit for ethical review has been detailed to further improve efficiency.

9. How to balance the relationship between reducing the burden on researchers and ethical review? What research is exempt from ethical review?

Taking into account that most basic research activities do not directly involve human trials, and some studies do not directly involve clinical diagnosis and treatment information of research participants, drawing on internationally accepted practices, in order to improve review efficiency and reduce unnecessary burdens on researchers, The Measures provide that "under the premise that the use of human information data or biological samples does not cause harm to the human body, and does not involve sensitive personal information or commercial interests," some cases involving human life science and medical research can be exempted from ethical review. It mainly includes:

(1) Using publicly available data obtained legally, or data generated by observation that does not interfere with public behavior;

2. Using anonymized information data to conduct research;

(3) Use existing human biological samples for research, the source of the biological samples used conforms to relevant regulations and ethical principles, the content and purpose of the research are within the scope of standardized informed consent, and do not involve the use of human germ cells, embryos, reproductive cloning, chimerism, heritable gene manipulation and other activities;

4. Use human cell lines or cell lines from biobank to conduct research, and the relevant contents and purposes of the research are within the scope authorized by the provider, and do not involve human embryos, reproductive cloning, chimerism, heritable gene manipulation and other activities.


  • Alstom vajh13yf1001aba - Automatic Trip Relay 220-250 V
  • ALSTOM Servo Inverter Type:ALSPA MV 1007-IT - - 3.0 kW
  • ALSTOM Cegelec Interface Modnet 1 / MB+ Fbk Mbp S1/S - Interface Module
  • Alstom Input / Output Card I/O Module SA44647.A - Module
  • Alstom Plug-in card Input/Output module SA44650.C - Module
  • ALSTOM Adjustment Module Keypad Alspa MV1000 - Keypad
  • Alstom Operating module Keypad Alspa MV1000 - Keypad
  • Alstom Plug-In Input/Output Module Sa 45629.B - Module
  • ALSTOM Adjustment Module Keyboard Alspa MV1000 - Keyboard
  • ALSTOM Control Set - 15 V 029.069642/26472/1011 - Voltage regulator
  • Alstom Input/Output Card Module SA44650.C - Module
  • Alstom Input / Output Card I/O Module - Module
  • Alsthom Alstom Plug-In Input/Output Module SA41630 B - Module
  • ALSTOM Servo Inverter Type: ALSPA MV 1007-IT - - 3.0 kW
  • Alstom Plug-In Input/Output I/O Module SA44647.A - Module
  • Alstom Plug-In Input/Output Module Sa 45629.B - Module
  • Alstom Plug-in card Input/Output module SA46623.B - Module
  • ALSTOM Control Module Keyboard Alspa MV1000 - Keyboard
  • Alstom Plug-In Input/Output Module SA46623.B - Module
  • Alstom Plug-In Input/Output Module SA44650.C - Module
  • Alstom Plug-In Input/Output Module SA43610.E - Module
  • Alstom Insertion Card Input / Output Module SA43610.E - Module
  • Alsthom Alstom Plug-In Input/Output Module SA41630 B - Module
  • Alstom Plug-In Input/Output I/O Module - Module
  • Alstom Plug-In Input/Output Module SA46623.B - Module
  • Alstom Plug-in card Input/Output I/O module SA44647.A - Module
  • Alstom Plug-in card Input/Output I/O module SA44647.A - Module
  • Alstom Plug-in card Input/Output module SA 45629.B - Module
  • ALSTOM Alspa VF Inverter Type : VF 4004b - - 1.5 Kw
  • Alstom Plug-In Input/Output Module SA46617.B - Module
  • Alstom PS 431 - Control Unit
  • Alstom Plug-In Input/Output Module Sa 46624.A - Module
  • Alstom Plug-In Input/Output Module SA44650.C - Module
  • Alstom Plug-In Input/Output Module SA43610.E - Module
  • ALSTOM Alspa MV1000 Frequency Type : Alspa MV1032 - - 15 Kw
  • Alstom Input/Output Card Module SA46617.B - Module
  • Alstom Input/Output Card Module Sa 45629.B - Module
  • Alstom Input/Output Card Module SA46623.B - Module
  • ALSTOM Servo-Converter Type : ALSPA MV 1007-IT - - 3.0 Kw
  • ALSTOM Frequency Type : ALSPA MD2000 - 43-400 (49-460)
  • ALSTOM Servo-Converter Type : ALSPA MV 1007 - - 3.0kW
  • Alstom PS 431 - Control
  • ALSTOM Alspa Cegelec Guide Value Transmitter 029.087.176/98N115099109 - Transmitter
  • Alstom Input/Output Card Module Sa 46624.A - Module
  • ALSTOM Control Set - 15 V 029.069642/26472/1011 - Voltage regulator
  • ALSTOM Alspa Module Control Set 029.111.890/27347/1018 - Module
  • ALSTOM Alspa Module Control Set 029.063.255/25443/1044 - Module
  • ALSTOM Alspa Cegelec Module Control Set 029.063.292/25943/1008 - Module
  • ALSTOM Microverter D 4-8/500/029.130.005 - Inverter
  • Alstom ISTAT M233 M233X2GUYECAL0A - Measurement unit M233X2GUYECAL0A NEW
  • ALSTOM Alspa Cegelec Guide Value Transmitter 029.087.176/98N115099109 - Transmitter
  • Alstom Input/Output Module SA 46624.A - Plug-in card
  • ALSTOM Cegelec Interface Modnet 1 / MB + Fbk - Mbp S1/S
  • ALSTOM MAE 00-11 - 8 Channel isolated analog i/o termination panel LC11-13 24118b
  • Alstom MMLG01 137945N - Test block electric panel 715209M T&D protection and control
  • ALSTOM Mae 00-11 - Channel Isolated Analog I/O Terminal Panel LC11-13 24118b Al
  • CONVERTEAM S20X4262/50 / S20X426250 - Module
  • CONVERTEAM MV530A4C1A / MV530A4C1A - Inverter
  • CONVERTEAM C100/5302 / C1005302 - Module
  • CONVERTEAM 20X4355B1L / 20X4355B1L - (new without box)
  • CONVERTEAM GM0020002 / GM0020002 - Module
  • CONVERTEAM P111-6052 / P1116052 - Module
  • Alstom PS 431 - Controller
  • ALSTOM Type : Alspa BC 32 - Brake Chopper Unit
  • ALSTOM Alspa MV500 SE23400075/MV502A4C1A - - 0.75kW Inverter
  • Alstom M30-Tx200 DIN931 - Hexagon screw stamped 8A B screw GE Alstom SW 46
  • Alstom Sa 46624.A - Plug-In Input/Output Module
  • ALSTOM Adjustment Module Keyboard Alspa MV1000 - Keyboard
  • Alstom PA20397/2186-03-H01 - Circuit Board
  • Alstom KBCH12001H12MEL 228633J - Relay Differential KBCH120
  • Alstom MMLG01 137945N - TestBlock Electric Panel 715209M T&D Protection & Control
  • Alstom KBCH12001H12MEL 228633J - Differential Relay KBCH120
  • Alstom MMLG01 137945N - Test Block Electrical Panel 715209M T&d Protection &
  • ALSTOM Mae 00-11 - 8 Channel Isolated Analog I/O Terminal Panel LC11-13 24118b
  • Alstom KBCH12001H12MEL 228633J - Differential Relay KBCH120 and extended warranty
  • Alstom MMLG01 137945N - Test Block Electrical Panel 715209M T & D Protection & De
  • Alstom DFI-110-0340F - DFI1100340F Diagnostic Flame Indicator
  • KCGG142 KCGG14201D20EEA - 287362J
  • ALSTOM MAE 00-11 - Channel isolated analog i/o termination panel LC11-13 24118b Al
  • KCGG122 KCGG12201DEED - 463055L and extended warranty
  • Alstom MMLG01 137945N - Test Block Electrical Panel T&D Protection & Control
  • Alstom 3FAFA5100A - Voltage Sensor TN7 112 003 Alstom T&D Protection & Control
  • Used ALSTOM PIB100 F 3BEB0169 - Board
  • Alstom Keypad - Alspa MV 1000
  • Alstom MMLG01 137945N - Test Block Electrical Panel 715209M T & D Protection &
  • ALSTOM PS441 - Overcurrent protection - Used
  • Alstom Power 2506305 - Circuit Board
  • ALSTOM PS431 - CONTROL UNIT
  • ALSTOM MV502S2B1A - 1 pc X Frequency Drive Alspa MV500
  • Alstom 3VAFS5500A - Voltage Sensor TN7105 002 Alstom T&D Protection & Control
  • ALSTOM MV507A2D1A - 1 pc X Frequency Drive Alspa MV500
  • KCGG KCGG12201L20EED - 655002M and extended warranty
  • ALSTOM TRVP059753000 - AGC3X-007 BLOCK ENCODER TRVP05975400
  • KCGG KCGG14202l20EEB - 654833M and extended warranty
  • Alstom 029 204 538 - cegelec Interface RS422/RS232 Alspa MV 1000
  • ALSTOM PIB100 F - 3BEB0169 Board
  • CONVERTEAM 8321-4002 / 83214002 - (new with box)
  • CONVERTEAM MVAJ14D1GA0774A / MVAJ14D1GA0774A - Relay
  • CONVERTEAM 8178-4002 / 81784002 - (new with box)
  • CONVERTEAM QTWIE2-VD4A / QTWIE2VD4A - (new with box)
  • CONVERTEAM A48DI-40DX-B7/95 / A48DI40DXB795 - Meter
  • CONVERTEAM V96LC/0-400RPM / V96LC0400RPM - Meter
  • CONVERTEAM A72DI-5-40X4/95 / A72DI540X495 - Meter
  • CONVERTEAM 8321-4002 / 83214002 - Module
  • CONVERTEAM 029.081-942 / 029081942 - Module
  • CONVERTEAM V96LC/0-600RPM / V96LC0600RPM - Meter
  • CONVERTEAM 20X4524B1L / 20X4524B1L - Module
  • CONVERTEAM EGS3C-ST11001 / EGS3CST11001 - Module
  • CONVERTEAM S8503-4001 / S85034001 - Module
  • CONVERTEAM MVAX12B1DA0752A / MVAX12B1DA0752A - Relay
  • CONVERTEAM 11P408ND8268/7 / 11P408ND82687 - (new without box)
  • CONVERTEAM MVAJ26L1BB0502A / MVAJ26L1BB0502A - Relay
  • CONVERTEAM C100/5120 / C1005120 - Module
  • CONVERTEAM D-984-0578 / D9840578 - Board
  • CONVERTEAM GDS1017-4001 / GDS10174001 - Enhancement Card
  • CONVERTEAM MBC101F1AD0761A / MBC101F1AD0761A - Module
  • CONVERTEAM GDS1006-4001 / GDS10064001 - Keypad
  • CONVERTEAM 25X8521/10 / 25X852110 - Module
  • CONVERTEAM VSELC1011A1AB / VSELC1011A1AB - (new without box)
  • CONVERTEAM RTS-13060102-R / RTS13060102R - Relay
  • CONVERTEAM LGPG-11101P55LEF / LGPG11101P55LEF - Relay
  • CONVERTEAM 203-399 / 203399 - Module
  • CONVERTEAM MV516A4C1 / MV516A4C1 - Inverter
  • CONVERTEAM SW867577-007 / SW867577007 - Module
  • CONVERTEAM MCGG22D1CD0503D / MCGG22D1CD0503D - Relay
  • CONVERTEAM MV506A4C1A / MV506A4C1A - Inverter
  • CONVERTEAM GM0025002 / GM0025002 - Module
  • CONVERTEAM MBCI01F1AD0511A / MBCI01F1AD0511A - Module